摘要
目的对比司美格鲁肽与达格列净治疗2型糖尿病(T2DM)合并非酒精性脂肪性肝病(NAFLD)患者的临床疗效。方法选取2022年2月至2023年3月南华大学附属第一医院收治的T2DM合并NAFLD患者102例,按用药方案分为A组与B组,每组51例。A组采用达格列净治疗,B组采用司美格鲁肽治疗。对比两组临床治疗效果。结果与治疗前相比,治疗后两组体重、体重指数、腰围、空腹血糖、胰岛素抵抗指数、谷丙转氨酶、谷草转氨酶、血浆胆固醇、血浆甘油三酯、内脏脂肪组织面积均较治疗前下降,且A组改善程度较B组明显更优,P<0.05。A组治疗总有效率高于B组,P<0.05。结论相比达格列净,司美格鲁肽治疗T2DM合并NAFLD患者的效果更佳,可有效控制患者血糖水平,减轻体重,改善其肝功能。
Objective:To compare the clinical efficacy of smegliptide and Dapagliflozin in treating patients with type 2 diabetes mellitus(T2DM)complicated with nonalcoholic fatty liver disease(NAFLD).Methods:102 patients with T2DM complicated with NAFLD admitted to the First Affiliated Hospital of South China University from February 2022 to March 2023 were selected and divided into group A and group B according to the medication regimen,with 51 cases in each group.Group A was treated with Dapagliflozin,while Group B was treated with Smegliptide.The clinical therapeutic effects of the two groups were compared.Results:Compared with before treatment,the body weight、body mass index、waist circumference、fasting blood glucose、insulin resistance index、alanine aminotransferase、aspartate aminotransferase、plasma cholesterol、plasma triglyceride and visceral adipose tissue area of the two groups decreased after treatment,and the improvement degree of group A was obviously better than that of group B,P<0.05.The total effective rate in group A was higher than that in group B,P<0.05.Conclusion:Compared with Dapagliflozin,Smegliptide is more effective in treating T2DM patients complicated with NAFLD,which can effectively control the blood sugar level,lose weight and improve their liver function.
作者
王源源
Wang Yuanyuan(Department of Endocrinology,First Affiliated Hospital of Nanhua University,Hengyang Hunan 421000,China)
出处
《生命科学仪器》
2024年第4期140-141,144,共3页
Life Science Instruments
